Is Dr Lalchand. Lab overvalued or undervalued?

As of 28 August 2025, the valuation grade for Dr Lalchand. Lab has moved from fair to expensive. The company is currently considered overvalued based on its financial ratios, including a PE ratio of 10.59, an EV to EBITDA of 11.17, and a ROCE of 4.54%. In comparison to its peers, Dr Lalchand. Lab's valuation stands out as it is significantly lower than Max Healthcare, which has a PE ratio of 93.61, and Apollo Hospitals, which has a PE ratio of 70.56.
Despite recent strong stock performance, with a year-to-date return of 44.56% compared to the Sensex's 2.48%, the fundamental metrics suggest that the stock is not justified at its current price of 24.43. The valuation appears to be inflated, particularly when compared to peers like Narayana Hrudaya, which is also classified as expensive but has a much higher PE ratio of 45.42. Overall, Dr Lalchand. Lab is overvalued in the current market environment.